# Shenhong Wu

## List of Publications by Year in Descending Order



| | | | |
|---|---|---|---|
| 93 papers | 5,093 citations | 33 h-index | 71 g-index |
| 94 ext. papers | 5,642 ext. citations | 5.5 avg, IF | 5.7 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 93 | Ibrutinib-associated dermatologic toxicities: A systematic review and meta-analysis.. *Critical Reviews in Oncology/Hematology*, **2022**, 174, 103696 | 7 | 0 |
| 92 | Risks and management of hypertension in cancer patients undergoing targeted therapy: a review.. *Clinical Hypertension*, **2022**, 28, 14 | 4.8 | 0 |
| 91 | Improving tolerability of pembrolizumab with weight based dosing: A meta-analysis.. *Journal of Clinical Oncology*, **2021**, 39, 2639-2639 | 2.2 | 0 |
| 90 | Tolerability of axitinib in advanced renal cell carcinoma: A meta-analysis.. *Journal of Clinical Oncology*, **2021**, 39, e16536-e16536 | 2.2 | 0 |
| 89 | Fatal Adverse Events Associated with Pembrolizumab in Cancer Patients: A Meta-Analysis. *Cancer Investigation*, **2020**, 38, 130-138 | 2.1 | 7 |
| 88 | Tolerability of single agent nivolumab in cancer patients: A meta-analysis.. *Journal of Clinical Oncology*, **2020**, 38, e15146-e15146 | 2.2 | |
| 87 | Tolerability of enzalutamide in prostate cancer: A meta-analysis.. *Journal of Clinical Oncology*, **2020**, 38, e15629-e15629 | 2.2 | |
| 86 | Risk of hypocalcemia in cancer patients treated with cabozantinib: A meta-analysis.. *Journal of Clinical Oncology*, **2020**, 38, e17067-e17067 | 2.2 | |
| 85 | Tolerability of dual checkpoint blockade with nivolumab and ipilimumab: A meta-analysis.. *Journal of Clinical Oncology*, **2020**, 38, e15149-e15149 | 2.2 | |
| 84 | Emerging therapeutic agents for genitourinary cancers. *Journal of Hematology and Oncology*, **2019**, 12, 89 | 22.4 | 22 |
| 83 | Incidence and risk of developing photosensitivity with targeted anticancer therapies. *Journal of the American Academy of Dermatology*, **2019**, 81, 1009-1011 | 4.5 | 2 |
| 82 | Increased Risk of Hypertension with Enzalutamide in Prostate Cancer: A Meta-Analysis. *Cancer Investigation*, **2019**, 37, 478-488 | 2.1 | 5 |
| 81 | Risk of hypertension in cancer patients treated with abiraterone: a meta-analysis. *Clinical Hypertension*, **2019**, 25, 12 | 4.8 | 10 |
| 80 | Risk of hypertension in Cancer patients treated with Abiraterone: a meta-analysis. *Clinical Hypertension*, **2019**, 25, 5 | 4.8 | 4 |
| 79 | Fatal adverse events associated with pembrolizumab in cancer patients: A meta-analysis.. *Journal of Clinical Oncology*, **2019**, 37, 2561-2561 | 2.2 | 1 |
| 78 | Current and Emerging Therapeutic Targets for Metastatic Renal Cell Carcinoma. *Current Oncology Reports*, **2018**, 20, 41 | 6.3 | 13 |
| 77 | Risk of Liver Toxicity with Nivolumab Immunotherapy in Cancer Patients. *Oncology*, **2018**, 94, 259-273 | 3.6 | 8 |

| | | | |
|---|---|---|---|
| 76 | An evaluation of nivolumab for the treatment of metastatic renal cell carcinoma. *Expert Opinion on Biological Therapy*, **2018**, 18, 695-705 | 5.4 | 2 |
| 75 | New treatment options for metastatic renal cell carcinoma with prior anti-angiogenesis therapy. *Journal of Hematology and Oncology*, **2017**, 10, 38 | 22.4 | 50 |
| 74 | Pigmentary changes in patients treated with targeted anticancer agents: A systematic review and meta-analysis. *Journal of the American Academy of Dermatology*, **2017**, 77, 902-910.e2 | 4.5 | 39 |
| 73 | Discontinuation of Everolimus Due to Related and Unrelated Adverse Events in Cancer Patients: A Meta-Analysis. *Cancer Investigation*, **2017**, 35, 552-561 | 2.1 | 3 |
| 72 | Increased risk of liver toxicity secondary to nivolumab therapy in the treatment of cancer.. *Journal of Clinical Oncology*, **2017**, 35, e14559-e14559 | 2.2 | 1 |
| 71 | Attributable Risk of Infection to mTOR Inhibitors Everolimus and Temsirolimus in the Treatment of Cancer. *Cancer Investigation*, **2016**, 34, 521-530 | 2.1 | 15 |
| 70 | Risk of hyperglycemia attributable to everolimus in renal cell and non□enal cell carcinoma patients: A meta-analysis.. *Journal of Clinical Oncology*, **2016**, 34, 515-515 | 2.2 | |
| 69 | Discontinuation of everolimus due to unrelated adverse events in cancer patients.. *Journal of Clinical Oncology*, **2016**, 34, e14020-e14020 | 2.2 | 0 |
| 68 | Risk of hyperglycemia attributable to everolimus in cancer patients: A meta-analysis. *Acta Onco□gica*, **2016**, 55, 1196-1203 | 3.2 | 12 |
| 67 | Update on the treatment of metastatic clear cell and non-clear cell renal cell carcinoma. *Biomarker Research*, **2015**, 3, 5 | 8 | 21 |
| 66 | Incidence and risk of xerosis with targeted anticancer therapies. *Journal of the American Academy of Dermatology*, **2015**, 72, 656-67 | 4.5 | 30 |
| 65 | Incidence and risk of high-grade stomatitis with mTOR inhibitors in cancer patients. *Cancer Investigation*, **2015**, 33, 70-7 | 2.1 | 23 |
| 64 | Reply to: "Skin moisturization for xerosis related to targeted anticancer therapies". *Journal of the American Academy of Dermatology*, **2015**, 73, e35-6 | 4.5 | |
| 63 | Incidence and risk of rash to mTOR inhibitors in cancer patients--a meta-analysis of randomized controlled trials. *Acta Onco□gica*, **2015**, 54, 124-32 | 3.2 | 9 |
| 62 | Novel therapy for advanced gastric cancer. *World Journal of Gastrointestinal Oncology*, **2015**, 7, 263-70 | 3.4 | 5 |
| 61 | Comparative analysis of the effectiveness of abiraterone before and after docetaxel in patients with metastatic castration-resistant prostate cancer. *World Journal of Clinical Oncology*, **2015**, 6, 64-72 | 2.5 | 5 |
| 60 | Comparative effectiveness of enzalutamide before and after chemotherapy in patients with metastatic castration-resistant prostate cancer: A meta-analysis.. *Journal of Clinical Oncology*, **2015**, 33, e16001-e16001 | 2.2 | |
| 59 | Risk of pneumonitis attributable to everolimus in cancer patients: A meta-analysis.. *Journal of Clinical Oncology*, **2015**, 33, e13574-e13574 | 2.2 | |

| | | | |
|---|---|---|---|
| 58 | Risk of anemia attributable to everolimus in patients with cancer: a meta-analysis of randomized controlled trials. *Anticancer Research*, **2015**, 35, 2333-40 | 2.3 | 5 |
| 57 | Efficacy of skin-directed therapy for cutaneous metastases from advanced cancer: a meta-analysis. *Journal of Clinical Oncology*, **2014**, 32, 3144-55 | 2.2 | 105 |
| 56 | Rash to the mTOR inhibitor everolimus: systematic review and meta-analysis. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2014**, 37, 266-71 | 2.7 | 18 |
| 55 | Cutaneous metastasis as an initial presentation of lung adenocarcinoma with KRAS mutation: a case report and literature review. *Stem Cell Investigation*, **2014**, 1, 6 | 5.1 | 3 |
| 54 | Risk of serious anemia with mTOR inhibitors in cancer patients: A meta-analysis of randomized controlled trials.. *Journal of Clinical Oncology*, **2014**, 32, e13534-e13534 | 2.2 | |
| 53 | Incidence and risk of stomatitis to mTOR inhibitors in cancer patients: A meta-analysis of randomized controlled trials.. *Journal of Clinical Oncology*, **2014**, 32, e17572-e17572 | 2.2 | |
| 52 | Risk of severe diarrhea associated with ipilimumab in cancer patients.. *Journal of Clinical Oncology*, **2014**, 32, 9634-9634 | 2.2 | |
| 51 | Incidence and risk of rash to mTOR inhibitors in cancer patients: A meta-analysis of randomized controlled trials.. *Journal of Clinical Oncology*, **2014**, 32, e17585-e17585 | 2.2 | |
| 50 | Risk of serious infection with mTOR inhibitors everolimus and temsirolimus in the treatment of cancer: A meta-analysis of randomized controlled trials.. *Journal of Clinical Oncology*, **2014**, 32, 2604-2604 | 2.2 | 2 |
| 49 | The efficacy of temozolomide for recurrent glioblastoma multiforme. *European Journal of Neurology*, **2013**, 20, 223-30 | 6 | 37 |
| 48 | Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis. *Investigational New Drugs*, **2013**, 31, 1078-86 | 4.3 | 76 |
| 47 | The risk of rash associated with ipilimumab in patients with cancer: a systematic review of the literature and meta-analysis. *Journal of the American Academy of Dermatology*, **2013**, 69, e121-8 | 4.5 | 100 |
| 46 | The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis. *Investigational New Drugs*, **2013**, 31, 787-97 | 4.3 | 49 |
| 45 | Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysis. *Journal of the American Academy of Dermatology*, **2013**, 69, 708-720 | 4.5 | 71 |
| 44 | Rash with the multitargeted kinase inhibitors nilotinib and dasatinib: meta-analysis and clinical characterization. *European Journal of Haematology*, **2013**, 90, 142-50 | 3.8 | 26 |
| 43 | Risk of liver toxicity with the angiogenesis inhibitor pazopanib in cancer patients. *Acta Oncologica*, **2013**, 52, 1202-12 | 3.2 | 36 |
| 42 | Alopecia with endocrine therapies in patients with cancer. *Oncologist*, **2013**, 18, 1126-34 | 5.7 | 35 |
| 41 | Pruritus to anticancer agents targeting the EGFR, BRAF, and CTLA-4. *Dermatologic Therapy*, **2013**, 26, 135-48 | 2.2 | 37 |

| | | | |
|---|---|---|---|
| 40 | The risk of nail changes with epidermal growth factor receptor inhibitors: a systematic review of the literature and meta-analysis. *Journal of the American Academy of Dermatology*, **2012**, 67, 400-8 | 4.5 | 50 |
| 39 | Risk of rash with the anti-HER2 dimerization antibody pertuzumab: a meta-analysis. *Breast Cancer Research and Treatment*, **2012**, 135, 347-54 | 4.4 | 24 |
| 38 | The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis. *Investigational New Drugs*, **2012**, 30, 1773-81 | 4.3 | 44 |
| 37 | Risk of rash in cancer patients treated with vandetanib: systematic review and meta-analysis. *Journal of Clinical Endocrinology and Metabolism*, **2012**, 97, 1125-33 | 5.6 | 41 |
| 36 | Bevacizumab and risk of hand-foot syndrome associated with chemotherapy.. *Journal of Clinical Oncology*, **2012**, 30, e13591-e13591 | 2.2 | 2 |
| 35 | Rash to mTOR inhibitor everolimus: Systematic review and meta-analysis.. *Journal of Clinical Oncology*, **2012**, 30, e19624-e19624 | 2.2 | 4 |
| 34 | Risk of rash with nilotinib: A systematic review of the literature and meta-analysis.. *Journal of Clinical Oncology*, **2012**, 30, 9088-9088 | 2.2 | |
| 33 | Risk of mineralocorticoid excess syndrome with CYP17 inhibitor abiraterone in prostate cancer patients.. *Journal of Clinical Oncology*, **2012**, 30, e15140-e15140 | 2.2 | |
| 32 | Risk of rash associated with lenalidomide in multiple myeloma and myelodisplastic syndrome: A systematic review of the literature and meta-analysis.. *Journal of Clinical Oncology*, **2012**, 30, e18571-e18571 | 2.2 | |
| 31 | Risk of skin rash with the proteasome inhibitor bortezomib: Updated systematic review and meta-analysis.. *Journal of Clinical Oncology*, **2012**, 30, 9092-9092 | 2.2 | |
| 30 | Risk of cardiac dysfunction with trastuzumab in breast cancer patients: a meta-analysis. *Cancer Treatment Reviews*, **2011**, 37, 312-20 | 14.4 | 78 |
| 29 | Inverse association between eczema and meningioma: a meta-analysis. *Cancer Causes and Control*, **2011**, 22, 1355-63 | 2.8 | 18 |
| 28 | Anti-vascular endothelial growth factor antibody bevacizumab reduced the risk of anemia associated with chemotherapy-A meta-analysis. *Acta Oncologica*, **2011**, 50, 997-1005 | 3.2 | 12 |
| 27 | Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. *JAMA - Journal of the American Medical Association*, **2011**, 305, 487-94 | 27.4 | 329 |
| 26 | Bevacizumab and Cancer Treatment-Related Mortality Reply. *JAMA - Journal of the American Medical Association*, **2011**, 305, 2291 | 27.4 | 3 |
| 25 | Sunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicities. *Oncologist*, **2011**, 16, 543-53 | 5.7 | 65 |
| 24 | Antiangiogenic agents for the treatment of nonsmall cell lung cancer: characterizing the molecular basis for serious adverse events. *Cancer Investigation*, **2011**, 29, 460-71 | 2.1 | 8 |
| 23 | Risk of Skin Rash in Proteasome Inhibitor Bortezomib: A Systematic Literature Review and Meta-Analysis. *Blood*, **2011**, 118, 5120-5120 | 2.2 | |

| | | | |
|---|---|---|---|
| 22 | Bevacizumab increases risk for severe proteinuria in cancer patients. *Journal of the American Society of Nephrology: JASN*, **2010**, 21, 1381-9 | 12.7 | 163 |
| 21 | Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials. *Acta Oncologica*, **2010**, 49, 287-97 | 3.2 | 217 |
| 20 | Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. *American Journal of Hypertension*, **2010**, 23, 460-8 | 2.3 | 179 |
| 19 | Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis. *Clinical Genitourinary Cancer*, **2009**, 7, 11-9 | 3.3 | 72 |
| 18 | Increased risk of high-grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy. *Cancer*, **2009**, 115, 1286-99 | 6.4 | 65 |
| 17 | Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. *Acta Oncologica*, **2009**, 48, 9-17 | 3.2 | 251 |
| 16 | Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. *Lancet Oncology, The*, **2009**, 10, 559-68 | 21.7 | 334 |
| 15 | Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. *Lancet Oncology, The*, **2008**, 9, 117-23 | 21.7 | 310 |
| 14 | Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. *JAMA - Journal of the American Medical Association*, **2008**, 300, 2277-85 | 27.4 | 568 |
| 13 | Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis. *Acta Oncologica*, **2008**, 47, 176-86 | 3.2 | 169 |
| 12 | Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. *Oncologist*, **2008**, 13, 1001-11 | 5.7 | 273 |
| 11 | Risk of Venous Thromboembolism with Thalidomide in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Blood*, **2008**, 112, 3820-3820 | 2.2 | 1 |
| 10 | Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer. *BJU International*, **2007**, 99, 1047-55 | 5.6 | 41 |
| 9 | Persistent hypocalcemia induced by zoledronic acid in a patient with androgen-independent prostate cancer and extensive bone metastases. *Clinical Genitourinary Cancer*, **2007**, 5, 403-5 | 3.3 | 14 |
| 8 | Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. *American Journal of Kidney Diseases*, **2007**, 49, 186-93 | 7.4 | 472 |
| 7 | The use of bisphosphonates in cancer patients. *Acta Oncologica*, **2007**, 46, 581-91 | 3.2 | 42 |
| 6 | The kinetic stability of MHC class II:peptide complexes is a key parameter that dictates immunodominance. *Immunity*, **2005**, 23, 29-40 | 32.3 | 182 |
| 5 | Replacement of the membrane proximal region of I-A(d) MHC class II molecule with I-E-derived sequences promotes production of an active and stable soluble heterodimer without altering peptide-binding specificity. *Journal of Immunological Methods*, **2005**, 300, 74-92 | 2.5 | 8 |

| | | | |
|---|---|---|---|
| 4 | Individual hydrogen bonds play a critical role in MHC class II: peptide interactions: implications for the dynamic aspects of class II trafficking and DM-mediated peptide exchange. *Immunological Reviews*, **1999**, 172, 239-53 | 11.3 | 33 |
| 3 | Alteration of a single hydrogen bond between class II molecules and peptide results in rapid degradation of class II molecules after invariant chain removal. *Journal of Experimental Medicine*, **1998**, 188, 2139-49 | 16.6 | 25 |
| 2 | The MHC class II-associated invariant chain-derived peptide clip binds to the peptide-binding groove of class II molecules. *Molecular Immunology*, **1996**, 33, 371-7 | 4.3 | 9 |
| 1 | Use of receptor antibodies to demonstrate membrane glucocorticoid receptor in cells from human leukemic patients. *FASEB Journal*, **1993**, 7, 1283-92 | 0.9 | 100 |